Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Journal of Lipid and Atherosclerosis
; : 8-14, 2019.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-765656
Responsible library:
WPRO
ABSTRACT
Choosing antithrombotic regimens for patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with stent placement is challenging. Until recently, the guidelines recommended warfarin-based triple therapy, which causes frequent major bleeding events in up to 12% of patients during the first year of treatment. The WOEST trial, however, revealed that dual therapy, by without aspirin, resulted in significantly lower bleeding risks with similar thromboembolic events to triple therapy. Subsequently, efforts to seek the optimal dual therapy regimens, especially with the combination of a non-vitamin K antagonist oral anticoagulant (NOAC), were initiated. This review highlights the evidence for dual therapy using an NOAC for patients with AF who underwent PCI, with an emphasis on reduced bleeding risk.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Atrial Fibrillation
/
Stents
/
Aspirin
/
Percutaneous Coronary Intervention
/
Hemorrhage
/
Anticoagulants
Type of study:
Practice guideline
Limits:
Humans
Language:
English
Journal:
Journal of Lipid and Atherosclerosis
Year:
2019
Document type:
Article